Cell Signaling

The epidermal growth factor receptor (EGFR) is a member of the ErbB family. It is involved in biological processes such as cell proliferation, angiogenesis, inhibition of apoptosis, adhesion, metastasis, and is associated with the progression of lung cancer [1-3].

Lung cancer is the leading cause of cancer death among both men and women in the United States. Because lung cancer is genetically heterogeneous, tailored therapy alone or in combination with chemotherapy would increase patient overall survival as compared with the one-size-fits-all chemotherapy. TP53-mutant lung cancer accounts for more than half of all lung cancer cases and is oftentimes more aggressive and resistant to chemotherapy. Directly targeting mutant p53 has not yet been successful, so identification of novel therapy targets and biomarkers in the TP53-mutant lung cancer is urgently needed to increase the overall survival in this subgroup.

In the United States, lung and bronchus cancers are the second most common types of cancer and are responsible for the largest number of deaths from cancer, with African Americans suffering disproportionately from lung and bronchus cancers. This disparity likely results from a complex interplay among social, psycho-social, lifestyle, environmental, health system, and biological determinants of health.

Intrahepatic cholangiocarcinoma (ICC), the second most frequent primary liver tumor, is a highly metastatic malignancy and often leads to disaster outcome in majority of patients, bringing significant challenges in the medical field [1].

FBXO9, an evolutionarily conserved member of the F-box protein family, functions as a substrate receptor within the Cullin 1-RING ubiquitin ligase complex (CRL1), also known as the SKP1-Cullin 1-F-box (SCF) complex [1].